Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab conditioning for haploidentical HSCT in MRD+ ALL
NCT06125106Phase 1Recruiting
- Sponsor
- Zhejiang University
- Start
- Nov 2023
- Primary completion
- Jan 2025
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of blinatumomab in acute lymphoblastic leukemia (ALL), sponsored by Zhejiang University. Primary endpoint: Progress-Free Survival at 1 year. Started Nov 2023; status: recruiting.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT06125106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06125106.